Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells clinical trials
How each study uses Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2023 (1)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 3
University of Pennsylvania (2) · City of Hope Medical Center (1)
Studies
Open first, then newest update. How each study uses Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade GliomasRecruitingPhase 1City of Hope Medical CenterNCT07544992Written as Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cellsHow we know
- CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial RadiotherapyActive, not recruitingPhase 1University of PennsylvaniaNCT06973096Written as CART-EGFR-IL13Ra2 cellsHow we know
- CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBMActive, not recruitingPhase 1University of PennsylvaniaNCT05168423Written as CART-EGFR-IL13Ra2 CellsHow we know